DOCSLIB.ORG

The Estrogens of the Pregnant Mare Kenneth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Estrogens of the Pregnant Mare Kenneth THE ESTROGENS OF THE PREGNANT MARE1 KENNETH SAVARD2 with the technical assistance of Downloaded from https://academic.oup.com/endo/article/68/3/411/2702391 by guest on 01 October 2021 BERNICE BURDULIS Endocrine Laboratory, University of Miami School of Medicine, Miami, Florida ABSTRACT The urinary ketonic estrogens were studied at monthly intervals in five pregnant mares. Estrone and equilin appear to be the principal components and equilenin a minor constituent of the mares' estrogens. The levels of equilin rise from the 4-5th months to equal and in some instances exceed those of estrone in the late months of pregnancy. A partition chromatographic method for the separation of the ketonic phenolic steroids of pregnant mares' urine is described. N THE early studies of mares' pregnancy urines, Girard and associates I (1, 2) observed that the Ring B unsaturated estrogens, equilin and equilenin, relative to the total estrogen titers, increased in the latter months of pregnancy, at a time when the total estrogen content of the urine diminished (3, 4). Prompted by the renewed interest in the biological origins and interrelationships of these unsaturated estrogens (5, 6, 7), and utilizing more refined analytical techniques (8), we have re-investigated this problem in several individual mares from the 5th month of pregnancy to its termination. METHODS Selection of Animals and Urine Collections. Thoroughbred, Quarterhorse and hybrid mares were initially studied in the 4th and 5th month after breeding in order to select those individuals secreting adequate amounts of urinary estrogens. Many mares ex- creted estrogen at very low levels, 20 mg. per day and less. Five mares were selected for the study; mares 1 and 2 were Quarterhorses, mares 3-5 were Thoroughbreds. Mares 1-4 were the property of a private stable and were kept in pasture land during the day- time in winter, and at night during the summer heat; otherwise the animals were brought to the barns where they were allowed water ad libitum at night in wintertime and during the day in summer. Urine was collected from the mares only while they were indoors in individual stalls. One such 8- to 12-hour urine collection was made from each mare at approximately the same time each month during the period of study. The estrogen titers, even on a 12-hour basis, were quite variable and in a few instances where com- plete 24-hour collections were made (mare 5), the estrogen excretion appeared to vary as Received June 24, 1960. 1 Supported in part by Grant No. C-4004, National Cancer Institute, United States Public Health Service. 2 Investigator, Howard Hughes Medical Institute. 411 412 SAVARD Volume 68 the volume of urine. The estrogen values on each urine collection, listed in Table 1, arc therefore given in mg. per liter of urine. Preparation of Estrogen Fraction. Treatment of the individual urines was as previ- ously described (7) and consisted of acidification to pH 1.0 with hydrochloric acid, ex- traction of the lipides with toluene during 0.5 and 2.5 hours of refluxing. The combined extracts were shaken with 10 per cent sodium carbonate and N sodium hydroxide; the sodium carbonate extracts (containing acidic material) and the final toluene layers (con- taining the neutral substances) were not studied. The sodium hydroxide extracts were adjusted to pH 8-9 and extracted several times with ether to provide the crude phenolic Downloaded from https://academic.oup.com/endo/article/68/3/411/2702391 by guest on 01 October 2021 fractions. The oily phenolic fractions were steam-distilled to remove non-estrogenic, volatile phenolic compounds, and the non-volatile portion from each urine specimen was separated into ketonic and non-ketonic fractions with Girard's reagent T. Chromatography of Ketonic Phenols. The chromatographic method of Haenni, Carol and Banes (8) for the non-ketonic estrogens of pregnant mares' urine, was modified to effect an adequate separation of estrone, equilin and equilenin. Celite (Johns-Manvillc TABLE 1. COMPOSITION OF KETONIC ESTROGEN FRACTION OF MARES' URINE DURING PREGNANCY Urinary Equilin Mare1 Month of Weeks before estrogen Estrone and Equilenin no. pregnancy foaling pe: liter % artefacts2 % mg.3 % 1 4 25 4.9 93 tr. tr. 5 21 31.7 85 9 tr. 6 17 34.2 73 16 6 7 13 43.7 49 38 8 8 9 13.2 — — .—. 9 44 11.4 47 36 11 2 6 21 50.8 60 28 7 7 18 71.6 46 41 8 8 14 29.1 49 31 15 9 10 24.3 36 51 9 10 6 13.5 29 53 13 11 2 7.9 — — — 3 5 25 44.8 85 4 6 6 21 17.4 68 22 5 7 17 32.9 55 33 8 8 13 45.5 45 42 8 9 9 25.8 39 48 8 10 5 17.6 55 33 7 11 1 5.8 92 tr. 2 4 5 27 75.5 88 6 1 6 23 111.3 64 26 5 7 19 53.7 41 43 11 8 15 41.7 37 46 12 9 10 42.4 40 48 7 10 5 53.2 — — -- 5 9 9 67.8 33 56 6 10 6 69.2 37 49 9 11 2 43.0 32 58 5 1 Mares 1-4 were the property of the Spring Hill Farm stables; mares Nos. 1 and 2 were Quarterhorse mares, Switchy-Mae and Cherryl Star, bred to Quiet Man, 1958; mares Nos. 3 and 4 were the Thoroughbreds, Menim and Plum Blossom, bred to Doctor Stanley, 1958. 2 Amounts of transformation products of equilin (see text) added. 3 Total estrogen determined by modified Kober test (for details, see text). * Mare foaled one month prematurely. March, 1961 ESTROGENS OF PREGNANT MARES 413 No. 545), washed according to Bauld (9), and IN sodium hydroxide (31.5 g. and 30 ml., respectively) were ground together in a mortar under ligroin-benzene (1:1 by volume). The impregnated Celite was transferred to a glass column (1.8 cm. i.d.) in small por- tions and packed as directed (9) to a height of 31-33 cm. Uniformity was determined by the use of Sudan Red; the flow-rate was usually approximately 1.5 ml. per minute for columns of these dimensions. The ketonic phenolic fraction was transferred to the column in ligroin: benzene (1:1) and developed in that solvent. Fractions (15 ml.) were collected on an automatic collector and alternate tubes were evaporated to dry ness. Freed of benzene, the residues Downloaded from https://academic.oup.com/endo/article/68/3/411/2702391 by guest on 01 October 2021 were dissolved in 5.0 ml. of freshly distilled methanol and examined in an ultraviolet- spectrophotometer in the range 350-220 m/u; weight of estrogen per tube was calculated from the intensity of the peak at 280 niju (10). When the zones of estrone and equilin had passed down the column, (tubes 75 and later) the solvent was changed and the develop- ment continued with benzene until the zone of equilenin had been eluted (tubes 120- 130). Little or no additional material was eluted with further volumes of benzene. The various steroids were characterized by their relative positions on the chromatograms, their ultraviolet absorption spectra (10) and by their absorption (700-220 mju) in sul- furic acid after two hours at room temperature (11). Variations in the concentration of sodium hydroxide, the nature of the developing solvent (hexane, cyclohexane, methyl cyclohexane, mixtures of the above with toluene), did not improve the operation of the column. It was found that temperatures above 25° C seriously impaired the resolution of the components; columns were therefore run in the range of 21-23° C. The weight of estrogenic material (determined by Brown modifica- tion of the Kober test (12)) applied to the column, ranged from 20-25 rag. of total estro- gen (expressed as estrone); the critical weight beyond which resolution was impaired appeared to be approximately 30 mg. and depended upon the content of equilin and equilenin, whose relative chromogenic values in the modified Kober test are 30 and 17%, respectively, relative to that of estrone (compare ref. 13). RESULTS AND DISCUSSION The results of the study of the components of the estrogen fraction of the monthly urine samples collected from Mare No. 3 are illustrated in Figure 1. It may be seen that an adequate separation of estrone and equilin took place on the chromatogram columns, the peaks being separated by approx- imately 25-30 tubes and the overlapping of the two zones amounting to 13- 18 per cent of the total weight of the two estrogens. Equilenin, on the other hand, was well separated, appearing only after the change in the mobile phase from 50 to 100% benzene; its mobility on these column corresponded approximately to that of estradiol-17/3. Two additional substances ap- peared in many of these chromatograms and were discernible by their ultraviolet absorption maxima. One compound was seen on occasion in the tubes immediately following the equilin zone or in the late (or trailing) tubes of that zone; the substance absorbed maximally at 274 m/x in meth- anol and in this respect resembled 8-dehydro-14-isoestrone (14). The second substance appeared in the tubes immediately preceding the equile- nin zone and is shown graphically (Fig. 1) as the "A9 E-l zone". This substance absorbed maximally at 263 m/x in methanol, resembling the spectrum of 9-dehydro-14-isoestrone (14). Both compounds are artefacts, 10 E-l 5th MONTH 6 th MONTH 7th MONTH 8th MONTH Pi 0.8 E- t E-l 0.6 I 0.4 1 0.2 68 ) 1 Z?E-IA E-| 0 20 40 60 80 100 120 20 40 60 80 100 120 20 40 60 80 100 120 140 20 40 60 80 100 120 TUBE NO.
Load more

Recommended publications
  • Clomifene Citrate(BANM, Rinnm) ⊗
    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
    [Show full text]
  • Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations
    CHEMICAL COMPOUNDS AS CARCINOGENIC AGENTS SECONDSUPPLEMENTARY REPORT: LITERATURE OF 1938 AND 1939 J. W. COOK AND E. L. KENNAWAY (From the Royal Cancer Hospital (Free), London, and the University of Glasgow) BIOLOGICALCONSIDERATIONS (Continued from page 428, Jitly 1940) II. Action of Carcinogenic Compounds in Difierent Species and Tissues A number of reports of the action of carcinogenic compounds on human tis- sues have appeared. Klar (601) developed a nodule on the forearm after completion of a series of experiments with 3:4-benzpyrene. He applied a solution of the hydrocarbon (0.25 per cent in benzol) to the skin of mice with a paint brush and for at least part of the period wore rubber gloves. He also conducted experiments, of which no description is given, with the powdered hydrocarbon contained in a glass vessel. Three months after the completion of the experiments a small nodule appeared on the dorsum of the left forearm, This was excised in May 1938 and described by Professor Huckel as a “ so- called benign calcifying epithelioma.” The growth extended into the subcu- taneous fatty tissue; the connection with the superficial epithelium is not described nor is it evident in the two photomicrographs which illustrate the report. The author does not state his age. Gordonoff and Walthard (562) record the occurrence of a tumor in a labo- ratory assistant, aged forty-two, engaged in applying methylcholanthrene (0.3 per cent in benzol) to the skin of mice. The site was in the nasolabial fold, at a spot often touched by the patient when smoking. The microscopic ap- pearance was that of a “ still well delimited stage of an incipient squamous- cell sarcoma.” Cottini and Mazzone (479) deliberately applied 3 :4-benzpyrene ( 1 per cent in benzene) to the skin, generally of the arm or thigh, of 26 patients with various cutaneous diseases, usually daily for periods up to 120 days.
    [Show full text]
  • The Reactivity of Human and Equine Estrogen Quinones Towards Purine Nucleosides
    S S symmetry Article The Reactivity of Human and Equine Estrogen Quinones towards Purine Nucleosides Zsolt Benedek †, Peter Girnt † and Julianna Olah * Department of Inorganic and Analytical Chemistry, Budapest University of Technology and Economics, Szent Gellért tér 4, H-1111 Budapest, Hungary; [email protected] (Z.B.); [email protected] (P.G.) * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: Conjugated estrogen medicines, which are produced from the urine of pregnant mares for the purpose of menopausal hormone replacement therapy (HRT), contain the sulfate conjugates of estrone, equilin, and equilenin in varying proportions. The latter three steroid sex hormones are highly similar in molecular structure as they only differ in the degree of unsaturation of the sterane ring “B”: the cyclohexene ring in estrone (which is naturally present in both humans and horses) is replaced by more symmetrical cyclohexadiene and benzene rings in the horse-specific (“equine”) hormones equilin and equilenin, respectively. Though the structure of ring “B” has only moderate influence on the estrogenic activity desired in HRT, it might still significantly affect the reactivity in potential carcinogenic pathways. In the present theoretical study, we focus on the interaction of estrogen orthoquinones, formed upon metabolic oxidation of estrogens in breast cells with purine nucleosides. This multistep process results in a purine base loss in the DNA chain (depurination) and the formation of a “depurinating adduct” from the quinone and the base. The point mutations induced in this manner are suggested to manifest in breast cancer development in the long run.
    [Show full text]
  • Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro
    Osgoode Hall Law School of York University Osgoode Digital Commons LLM Theses Theses and Dissertations 8-27-2018 Toxic Enactments: Materializing Estrogen and Regulation Under Canada's Food and Drugs Act, 1939-1953 Lara Jessie Tessaro Follow this and additional works at: https://digitalcommons.osgoode.yorku.ca/llm Part of the Legal History Commons TOXIC ENACTMENTS: MATERIALIZING ESTROGEN AND REGULATION UNDER CANADA’S FOOD AND DRUGS ACT, 1939-1953 LARA TESSARO A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF LAWS GRADUATE PROGRAM IN LAW OSGOODE HALL LAW SCHOOL, YORK UNIVERSITY TORONTO, ONTARIO August 2018 © Lara Tessaro, 2018 ABSTRACT The study describes how estrogen was standardized in Canada, in the 1940s and early 1950s, under the Food and Drugs Act. Contributing to interdisciplinary conversations, it provides an empirical case of how regulatory practices enact material realities. Using archival material, the study describes how estrogen was achieved, in part, through heterogeneous practices of the Canadian Committee on Pharmacopoeial Standards, National Health, and government solicitors. These regulators disagreed on whether, how, and by whom estrogens should be standardized. Rather than resolve these disagreements, Canada enacted multiple regulations purporting to standardize estrogen, and government solicitors practiced “techniques of validating” to render the regulations as lawful. I argue that these regulatory enactments materialized estrogen as a potent, unpredictable, and multiple object. Further, I show how estrogen spawned novel regulatory techniques in Canada, particularly the use of consumer product labels. In this way, estrogen catalyzed an early example of risk regulation in Canada.
    [Show full text]
  • Pp375-430-Annex 1.Qxd
    ANNEX 1 CHEMICAL AND PHYSICAL DATA ON COMPOUNDS USED IN COMBINED ESTROGEN–PROGESTOGEN CONTRACEPTIVES AND HORMONAL MENOPAUSAL THERAPY Annex 1 describes the chemical and physical data, technical products, trends in produc- tion by region and uses of estrogens and progestogens in combined estrogen–progestogen contraceptives and hormonal menopausal therapy. Estrogens and progestogens are listed separately in alphabetical order. Trade names for these compounds alone and in combination are given in Annexes 2–4. Sales are listed according to the regions designated by WHO. These are: Africa: Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Congo, Côte d'Ivoire, Democratic Republic of the Congo, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, South Africa, Swaziland, Togo, Uganda, United Republic of Tanzania, Zambia and Zimbabwe America (North): Canada, Central America (Antigua and Barbuda, Bahamas, Barbados, Belize, Costa Rica, Cuba, Dominica, El Salvador, Grenada, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Puerto Rico, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago), United States of America America (South): Argentina, Bolivia, Brazil, Chile, Colombia, Dominican Republic, Ecuador, Guyana, Paraguay,
    [Show full text]
  • Conjugated Estrogens Sustained Release Tablets) 0.3 Mg, 0.625 Mg, and 1.25 Mg
    PRODUCT MONOGRAPH PrPREMARIN® (conjugated estrogens sustained release tablets) 0.3 mg, 0.625 mg, and 1.25 mg ESTROGENIC HORMONES ® Wyeth Canada Date of Revision: Pfizer Canada Inc., Licensee December 1, 2014 17,300 Trans-Canada Highway Kirkland, Quebec H9J 2M5 Submission Control No: 177429 PREMARIN (conjugated estrogens sustained release tablets) Page 1 of 46 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ...........................................................................3 INDICATIONS AND CLINICAL USE ................................................................................3 CONTRAINDICATIONS ......................................................................................................4 WARNINGS AND PRECAUTIONS ....................................................................................4 ADVERSE REACTIONS ....................................................................................................14 DRUG INTERACTIONS ....................................................................................................20 DOSAGE AND ADMINISTRATION ................................................................................23 OVERDOSAGE ...................................................................................................................25 ACTION AND CLINICAL PHARMACOLOGY ...............................................................25 STORAGE AND STABILITY ............................................................................................28
    [Show full text]
  • Pharmaceutical and Veterinary Compounds and Metabolites
    PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES High quality reference materials for analytical testing of pharmaceutical and veterinary compounds and metabolites. lgcstandards.com/drehrenstorfer [email protected] LGC Quality | ISO 17034 | ISO/IEC 17025 | ISO 9001 PHARMACEUTICAL AND VETERINARY COMPOUNDS AND METABOLITES What you need to know Pharmaceutical and veterinary medicines are essential for To facilitate the fair trade of food, and to ensure a consistent human and animal welfare, but their use can leave residues and evidence-based approach to consumer protection across in both the food chain and the environment. In a 2019 survey the globe, the Codex Alimentarius Commission (“Codex”) was of EU member states, the European Food Safety Authority established in 1963. Codex is a joint agency of the FAO (Food (EFSA) found that the number one food safety concern was and Agriculture Office of the United Nations) and the WHO the misuse of antibiotics, hormones and steroids in farm (World Health Organisation). It is responsible for producing animals. This is, in part, related to the issue of growing antibiotic and maintaining the Codex Alimentarius: a compendium of resistance in humans as a result of their potential overuse in standards, guidelines and codes of practice relating to food animals. This level of concern and increasing awareness of safety. The legal framework for the authorisation, distribution the risks associated with veterinary residues entering the food and control of Veterinary Medicinal Products (VMPs) varies chain has led to many regulatory bodies increasing surveillance from country to country, but certain common principles activities for pharmaceutical and veterinary residues in food and apply which are described in the Codex guidelines.
    [Show full text]
  • Estriol Prevention of Mammary Carcinoma Induced by 7,12-Dimethylbenzanthracene and Procarbazine1
    (CANCER RESEARCH 35, 1341 1353, May 1975] Estriol Prevention of Mammary Carcinoma Induced by 7,12-Dimethylbenzanthracene and Procarbazine1 Henry M. Lemon Section of Oncology, Department of Internal Medicine, The University of Nebraska Medical Center, 42nd Street and Dewey Avenue, Omaha. Nebraska 68105 SUMMARY hexestrol, 0.60 mg/pellet, did not alter breast cancer incidence in 220 additional rats. Estrogen-treated rats The concentration of estrogenic, androgenic, progesta- usually sustained a mean 0.6 to 8.9% reduction of body tional, and adrenocortical steroid hormones in body fluids growth for the first 6 to 8 months of observation; this did of mature intact Sprague-Dawley female rats was increased not correlate with the breast carcinoma-suppressive activi by s.c. implantation of 5 to 7 mg NaCl pellets containing 1 ties of individual steroids. to 20% steroid 48 hr before administration p.o. of either Single implantation of 0.60 mg estriol 48 hr before 7,12-dimethylbenz(a)anthracene or procarbazine. The inci dimethylbenzanthracene p.o. or sustained implantation dence of rats developing one or more mammary carcinomas every 2 months of 10% estriol pellets beginning 24 hr after in each treated group was compared to that observed in si carcinogen exposure failed significantly to alter mammary multaneously treated groups receiving only the carcinogen, carcinoma development after dimethylben/anthracene ad steroid, or no treatment whatsoever, with weekly observa ministration. tion of all rats until palpably growing tumors were biopsied Inhibition of mammary carcinogenesis induced by these and proven carcinomatous or until death occurred from two dissimilar carcinogens in intact mature rats using other causes determined by autopsy.
    [Show full text]
  • Steroidal Estrogens
    FINAL Report on Carcinogens Background Document for Steroidal Estrogens December 13 - 14, 2000 Meeting of the NTP Board of Scientific Counselors Report on Carcinogens Subcommittee Prepared for the: U.S. Department of Health and Human Services Public Health Service National Toxicology Program Research Triangle Park, NC 27709 Prepared by: Technology Planning and Management Corporation Canterbury Hall, Suite 310 4815 Emperor Blvd Durham, NC 27703 Contract Number N01-ES-85421 Dec. 2000 RoC Background Document for Steroidal Estrogens Do not quote or cite Criteria for Listing Agents, Substances or Mixtures in the Report on Carcinogens U.S. Department of Health and Human Services National Toxicology Program Known to be Human Carcinogens: There is sufficient evidence of carcinogenicity from studies in humans, which indicates a causal relationship between exposure to the agent, substance or mixture and human cancer. Reasonably Anticipated to be Human Carcinogens: There is limited evidence of carcinogenicity from studies in humans which indicates that causal interpretation is credible but that alternative explanations such as chance, bias or confounding factors could not adequately be excluded; or There is sufficient evidence of carcinogenicity from studies in experimental animals which indicates there is an increased incidence of malignant and/or a combination of malignant and benign tumors: (1) in multiple species, or at multiple tissue sites, or (2) by multiple routes of exposure, or (3) to an unusual degree with regard to incidence, site or type of tumor or age at onset; or There is less than sufficient evidence of carcinogenicity in humans or laboratory animals, however; the agent, substance or mixture belongs to a well defined, structurally-related class of substances whose members are listed in a previous Report on Carcinogens as either a known to be human carcinogen, or reasonably anticipated to be human carcinogen or there is convincing relevant information that the agent acts through mechanisms indicating it would likely cause cancer in humans.
    [Show full text]
  • The Rabbits Are Prepared ..." - the Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J
    Journal für Reproduktionsmedizin und Endokrinologie – Journal of Reproductive Medicine and Endocrinology – Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie "The Rabbits are Prepared ..." - The Development of Ethinylestradiol and Ethinyltestosterone Frobenius W J. Reproduktionsmed. Endokrinol 2011; 8 (Sonderheft 1), 32-57 www.kup.at/repromedizin Online-Datenbank mit Autoren- und Stichwortsuche Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D·I·R, EFA, OEGRM, SRBM/DGE Indexed in EMBASE/Excerpta Medica/Scopus Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz FERRING-Symposium digitaler DVR 2021 Mission possible – personalisierte Medizin in der Reproduktionsmedizin Was kann die personalisierte Kinderwunschbehandlung in der Praxis leisten? Freuen Sie sich auf eine spannende Diskussion auf Basis aktueller Studiendaten. SAVE THE DATE 02.10.2021 Programm 12.30 – 13.20Uhr Chair: Prof. Dr. med. univ. Georg Griesinger, M.Sc. 12:30 Begrüßung Prof. Dr. med. univ. Georg Griesinger, M.Sc. & Dr. Thomas Leiers 12:35 Sind Sie bereit für die nächste Generation rFSH? Im Gespräch Prof. Dr. med. univ. Georg Griesinger, Dr. med. David S. Sauer, Dr. med. Annette Bachmann 13:05 Die smarte Erfolgsformel: Value Based Healthcare Bianca Koens 13:15 Verleihung Frederik Paulsen Preis 2021 Wir freuen uns auf Sie! Development of Ethinylestradiol and Ethinyltestosterone “The Rabbits are Prepared …” – The Development of Ethinylestradiol and Ethinyltestosterone W. Frobenius In an exciting scientific neck-and-neck race, European and American scientists in the late 1920s and early 1930s isolated the ovarian, placental, and testicular hormones. At the same time the constitution of the human sex steroids was elucidated. However, it soon emerged that with oral administration the therapeutic value of the natural substances was extremely limited.
    [Show full text]
  • Ynthesis and Structure-Activity Relationships of Some 4-Substituted Pyrazole and Isoxazole Inhibitors of Liveralcohol Dehydrogenase
    AN ABSTRACT OF THE THESIS OF Douglas Robert Henry for the degree of Doctor of Philosophy in Pharmacy presented on July 10, 1980 Title: I. SYNTHESIS AND STRUCTURE- ACTIVITY RELATIONSHIPS OF SOME 4-SUBSTITUTED PYRAZOLE AND ISOXAZOLE INHIBITORS OF LIVER ALCOHOL DEHYDROGENASE II. THE USE OF MOLECULAR CONNECTIVITY IN THE MULTIVARIATE CLASSIFICATION OF DRUG MOLECULES Redacted for Privacy Abstract Approved: U Dr. John H. Block In a two part thesis, studies were made of two different types of structure-activity relationships. The first part consists of the synthesis and biological evaluation of a number of 4-substituted pyrazoles and isoxazoles as inhibitors of liver alcohol dehydrogenase. In an effort to better define the steric and electronic effects of substituents, the inhibitory potencies ofthe compounds were determined in vitro, and these were correlated with the lipophilicity parameter IFand with several steric and electronic substituent constants. Lipophilicity showed the most significant relationship with activity. Electronic terms were less significant, but a consistently negative slope coefficient for these terms suggests that a positive charge develops on the pyrazole ring during interaction with LADH, which is not consistent with a previously proposed anionic intermediate. In the second part of the thesis, retrospective research was performed to determine the usefulness of fragment and whole-molecule molecular connectivity (MC) indices in the multivariate classification of drug structures. Initially, using a template method of position assignment, a number of diphenylmethyl-based compounds from a previous study were examined using linear and quadratic discriminant analysis. Relative molar refraction was compared with several fragment MC values as descriptor indices.
    [Show full text]
  • Koong-Dissertationdoctoral
    Copyright by Luke Yun-Kong Koong 2014 The Dissertation Committee for Luke Yun-Kong Koong Certifies that this is the approved version of the following dissertation: THE DIRECT EFFECTS OF ESTRADIOL AND SEVERAL XENOESTROGENS ON CELL NUMBERS OF EARLY- VS. LATE- STAGE PROSTATE CANCER CELLS Committee: Cheryl S Watson, PhD, Mentor Darren Boehning, PhD, Chair Gracie Vargas, PhD Randall M Goldblum, MD Nancy Ing, DVM, PhD _______________________________ Dean, Graduate School THE DIRECT EFFECTS OF ESTRADIOL AND SEVERAL XENOESTROGENS ON CELL NUMBERS OF EARLY- VS. LATE- STAGE PROSTATE CANCER CELLS by Luke Yun-Kong Koong, BS Dissertation Presented to the Faculty of the Graduate School of The University of Texas Medical Branch in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy The University of Texas Medical Branch December, 2014 Dedication This dissertation is dedicated to my family, whom has supported me with love and encouragement throughout my life; my friends, who push me to greater heights; and most importantly God, who continues to bless me every day with life and joy. Acknowledgements I would like to acknowledge my mentor, Cheryl S Watson, who has guided me through my graduate work. She has shown me how to be a true scientist and a responsible steward of our environment. I am forever grateful for the avenues she has opened up for my life and career. Additionally, I would like to thank my committee members for all of their constructive ideas throughout my project, as well as encouragement along the way. Another key figure in my graduate career is Jennifer Jeng of the Watson laboratory, who helped teach me many of the assays used in this study, and who was also available for advice and suggestions.
    [Show full text]